Esbriet (pirfenidone): Important safety update and new recommendations to prevent Drug-Induced Liver Injury (DILI)
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Esbriet
|
| Active substance |
Pirfenidone
|
| Therapeutic area (MeSH) |
Idiopathic Pulmonary Fibrosis
|
| Procedure number |
EMEA/H/C/002154/II/0066/G
|
| Regulatory outcome |
Variation
|
| DHPC type |
Type II variation
|
| Human ATC code |
L04AX05
|
| Dissemination date |
29/10/2020
|